By Dan Victor
In a time where investors are closely scrutinizing software-as-a-service companies against the threat of disruption from artificial intelligence, the margin for error is, if not inexistent, then very slim indeed.
Phreesia Inc., a Barron's stock pick from 2025, is a poster child of the " SaaSpocalypse," caught up in both its industry headwinds and some missteps of its own undoing. The most recent catalyst came from earnings reported on March 30. Shares of the healthcare technology small-cap known for its patient intake and medical billings platform plunged by 30% after management revised sharply lower its full year fiscal 2027 growth outlook from a prior 15% midpoint estimate to 7%.
The stock is now down 54% from our last update and we're taking this disappointment as a sign to move on from the pick and drop coverage.
As DA Davidson analyst Clark Wright says in his note recapping Phreesia's fourth quarter earnings, "there are several moving pieces to the story." He describes the financial results as solid, with quarterly revenue climbing by 16% year over year while adjusted earnings before interest, taxes, depreciation, and amortization (Ebitda) of $29.4 million surged compared with $16.4 million in the period last year. Fiscal 2026 marked the company's first year with a positive net income as a public company, generating $54.4 million in free cash flow, a sizable figure compared with its current $480 million market capitalization.
If only it were that easy. In this case, expectations are everything, and it seems the market is more concerned with the continuing weakness in Phreesia's network solutions group. The segment was previously seen as a growth driver by offering a regulatory compliant channel for pharmaceutical companies to communicate and advertise to patients directly, diversifying away from the SaaS platform.
The lowered revenue guidance for the year ahead was centered precisely in network solutions as life sciences clients remain hesitant to commit to larger spending budgets. During the earnings conference call with investors, Phreesia CEO Chaim Indig cited "challenges in FDA guidelines, insurance coverage, patient utilization, and provider reimbursement" to explain its tough market environment for that side of the business that has created variability in its financial forecasts.
Despite that uncertainty, some analysts are taking a glass half full approach. Across 20 Wall Street analysts tracked by FactSet, 18 have a buy rating on shares of Phreesia including 15 reiterating their bullish view despite the company's update and share price collapse.
Brian Tanquilut at Jefferies maintained his buy rating on Phreesia while adjusting the price target to $20, from a prior $25, writing in a note, "we think the stock valuation is undemanding now." Phreesia's adjusted Ebitda target for the year ahead is around $130 million, representing a 28% annual increase and implying shares are trading at just four times enterprise value or six times forward price to earnings. He points to the new company guidance as conservative, suggesting that any positive development this year should be enough to "inflect the stock."
It may sound compelling, but we've already taken a shot and won't be participating this time around.
As we see it, the bigger challenge facing Phreesia is the continuing repricing in the market toward these types of small-cap tech names with a questionable competitive moat. Rapid advancements in artificial intelligence that facilitate the creation of software applications may limit Phreesia's ability to expand its market opportunity or raise pricing. That lack of clarity may justify a structural valuation discount that limits the upside in the stock and keeps it volatile going forward.
-- Stay tuned for the next live Q&A! Watch the Barron's Investor Circle page for the sign-up link -- Share your questions and thoughts in the "Conversation" section below to engage directly with the author and our community -- Receive alerts about more content from this author by clicking "Follow" next to the author byline at top
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 01, 2026 04:18 ET (08:18 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments